Detalhe da pesquisa
1.
A Novel Triple-Action Inhibitor Targeting B-Cell Receptor Signaling and BRD4 Demonstrates Preclinical Activity in Chronic Lymphocytic Leukemia.
Int J Mol Sci
; 23(12)2022 Jun 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-35743155
2.
BET inhibition reforms the immune microenvironment and alleviates T cell dysfunction in chronic lymphocytic leukemia.
JCI Insight
; 9(10)2024 May 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38775157
3.
Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-Cov-2 Infection In Vitro.
Biomedicines
; 9(4)2021 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-33919584